Literature DB >> 15226518

The use of the British Isles Lupus Assessment Group (BILAG) index as a valid tool in assessing disease activity in childhood-onset systemic lupus erythematosus.

S D Marks1, C Pilkington, P Woo, M J Dillon.   

Abstract

OBJECTIVES: The British Isles Lupus Assessment Group (BILAG) index is a standardized systemic lupus erythematosus (SLE) disease activity assessment. The main aim of this study was to correlate the BILAG index with laboratory measures of disease activity in childhood-onset SLE with and without biopsy-proven lupus nephritis.
METHOD: Prospective observational comparison study of the BILAG index in 21 SLE patients under 18 yr of age over a 12-month period in a tertiary referral paediatric outpatient clinic.
RESULTS: Eleven patients with lupus non-nephritis and 10 patients with lupus nephritis were reviewed. The lupus nephritis patients had significantly (P<0.001) more admissions over a similar time interval since diagnosis. The renal BILAG disease activity scores were significantly greater (P = 0.013) in the lupus nephritis group (range 1-9, median 3.0, compared with 0-3 and 1.0 in the lupus non-nephritis group). The total BILAG scores and patient visual analogue scores (VAS) were higher in the lupus nephritis groups, unlike the lower physician VAS, but these differences were not statistically significant compared with other laboratory indices of disease activity.
CONCLUSIONS: The BILAG index is a useful tool in monitoring disease activity in children and adolescents with SLE. The data collected for the BILAG index can be used serially and effectively by different clinicians over time to enable recording of disease status at sequential assessments. The lower patient VAS in the lupus non-nephritis group was not significant and may reflect the patients' own perception of lethargy at times of increased disease activity.

Entities:  

Mesh:

Year:  2004        PMID: 15226518     DOI: 10.1093/rheumatology/keh284

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  12 in total

1.  The vascular phenotype of children with systemic lupus erythematosus.

Authors:  Catherine Quinlan; Jameela Kari; Clarissa Pilkington; John Deanfield; Rukshana Shroff; Stephen D Marks; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2015-05-23       Impact factor: 3.714

2.  Incident vertebral fractures among children with rheumatic disorders 12 months after glucocorticoid initiation: a national observational study.

Authors:  Celia Rodd; Bianca Lang; Timothy Ramsay; Nathalie Alos; Adam M Huber; David A Cabral; Rosie Scuccimarri; Paivi M Miettunen; Johannes Roth; Stephanie A Atkinson; Robert Couch; Elizabeth A Cummings; Peter B Dent; Janet Ellsworth; John Hay; Kristin Houghton; Roman Jurencak; Maggie Larché; Claire LeBlanc; Kiem Oen; Claire Saint-Cyr; Robert Stein; David Stephure; Shayne Taback; Brian Lentle; Maryann Matzinger; Nazih Shenouda; David Moher; Frank Rauch; Kerry Siminoski; Leanne M Ward
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-01       Impact factor: 4.794

3.  Basophil count, a marker for disease activity in systemic lupus erythematosus.

Authors:  Peifen Liang; Ying Tang; Sha Fu; Jun Lv; Bo Liu; Min Feng; Jinggao Li; Deyuan Lai; Xia Wan; Anping Xu
Journal:  Clin Rheumatol       Date:  2014-11-19       Impact factor: 2.980

4.  Prevalent vertebral fractures among children initiating glucocorticoid therapy for the treatment of rheumatic disorders.

Authors:  A M Huber; I Gaboury; D A Cabral; B Lang; A Ni; D Stephure; S Taback; P Dent; J Ellsworth; C LeBlanc; C Saint-Cyr; R Scuccimarri; J Hay; B Lentle; M Matzinger; N Shenouda; D Moher; F Rauch; K Siminoski; L M Ward
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-04       Impact factor: 4.794

5.  Incident Vertebral Fractures and Risk Factors in the First Three Years Following Glucocorticoid Initiation Among Pediatric Patients With Rheumatic Disorders.

Authors:  Claire M A LeBlanc; Jinhui Ma; Monica Taljaard; Johannes Roth; Rosie Scuccimarri; Paivi Miettunen; Bianca Lang; Adam M Huber; Kristin Houghton; Jacob L Jaremko; Josephine Ho; Nazih Shenouda; Mary Ann Matzinger; Brian Lentle; Robert Stein; Anne Marie Sbrocchi; Kiem Oen; Celia Rodd; Roman Jurencak; Elizabeth A Cummings; Robert Couch; David A Cabral; Stephanie Atkinson; Nathalie Alos; Frank Rauch; Kerry Siminoski; Leanne M Ward
Journal:  J Bone Miner Res       Date:  2015-05-26       Impact factor: 6.741

6.  Urine biomarkers for monitoring juvenile lupus nephritis: a prospective longitudinal study.

Authors:  Louise Watson; Kjell Tullus; Clarissa Pilkington; Christine Chesters; Stephen D Marks; Paul Newland; Caroline A Jones; Michael W Beresford
Journal:  Pediatr Nephrol       Date:  2013-11-16       Impact factor: 3.714

7.  Increased soluble phagocytic receptors sMer, sTyro3 and sAxl and reduced phagocytosis in juvenile-onset systemic lupus erythematosus.

Authors:  Lucy Ballantine; Angela Midgley; David Harris; Ella Richards; Sarah Burgess; Michael W Beresford
Journal:  Pediatr Rheumatol Online J       Date:  2015-04-10       Impact factor: 3.054

8.  International validation of a urinary biomarker panel for identification of active lupus nephritis in children.

Authors:  Eve Mary Dorothy Smith; Andrea Lyn Jorgensen; Angela Midgley; Louise Oni; Beatrice Goilav; Chaim Putterman; Dawn Wahezi; Tamar Rubinstein; Diana Ekdawy; Rachel Corkhill; Caroline Ann Jones; Stephen David Marks; Paul Newland; Clarissa Pilkington; Kjell Tullus; Michael William Beresford
Journal:  Pediatr Nephrol       Date:  2016-09-03       Impact factor: 3.714

9.  Pharmacokinetics, Pharmacodynamics and Preliminary Observations for Clinical Activity and Safety of Multiple Doses of Human Mouse Chimeric Anti-CD22 Monoclonal Antibody (SM03) in Chinese Patients with Systemic Lupus Erythematosus.

Authors:  Qian Zhao; Xia Chen; Jing Li; Ji Jiang; Mengtao Li; Wen Zhong; Zhengdong Li; Shui-On Leung; Fengchun Zhang; Pei Hu
Journal:  Clin Drug Investig       Date:  2016-11       Impact factor: 3.580

10.  The pro-inflammatory potential of T cells in juvenile-onset systemic lupus erythematosus.

Authors:  Lucy E Ballantine; Joanne Ong; Angela Midgley; Louise Watson; Brian F Flanagan; Michael W Beresford
Journal:  Pediatr Rheumatol Online J       Date:  2014-01-16       Impact factor: 3.054

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.